Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia: Comparison with flavopiridol.

被引：3
|
作者：
Chen, Rong [1 ]
Wierda, William G. [1 ]
Benaissa, Sherri [1 ]
Hoch, Ute [2 ]
Hawtin, Rachael E. [2 ]
Fox, Judith A. [2 ]
Keating, Michael J. [1 ]
Gandhi, Varsha [1 ]
Plunkett, William [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Sunesis Pharmaceut, San Francisco, CA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3112.3112
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3112
引用
收藏
页码：915A / 915A
页数：1
相关论文
共 50 条
  • [21] ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
    Mahoney, Emilia
    Lucas, David M.
    Gupta, Sneha V.
    Wagner, Amy J.
    Herman, Sarah E. M.
    Smith, Lisa L.
    Yeh, Yuh-Ying
    Andritsos, Leslie
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Blum, Kristie A.
    Zhang, Xiaoli
    Lehman, Amy
    Kong, Hui
    Gurcan, Metin
    Grever, Michael R.
    Johnson, Amy J.
    Byrd, John C.
    BLOOD, 2012, 120 (06) : 1262 - 1273
  • [22] Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia
    Blachly, James S.
    Byrd, John C.
    Grever, Michael
    SEMINARS IN ONCOLOGY, 2016, 43 (02) : 265 - 273
  • [23] Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
    Tong, Wei-Gang
    Chen, Rong
    Plunkett, William
    Siegel, David
    Sinha, Rajni
    Harvey, R. Donald
    Badros, Ashraf Z.
    Popplewell, Leslie
    Coutre, Steven
    Fox, Judith A.
    Mahadocon, Kristi
    Chen, Tianling
    Kegley, Peggy
    Hoch, Ute
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 3015 - 3022
  • [24] Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis
    Jorda, EG
    Verdaguer, E
    Canudas, AM
    Jiménez, A
    Bruna, A
    Caelles, C
    Bravo, R
    Escubedo, E
    Pubill, D
    Camarasa, J
    Pallàs, M
    Camins, A
    NEUROPHARMACOLOGY, 2003, 45 (05) : 672 - 683
  • [25] Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro
    Cihalova, Daniela
    Staud, Frantisek
    Ceckova, Martina
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) : 105 - 116
  • [26] Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro
    Daniela Cihalova
    Frantisek Staud
    Martina Ceckova
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 105 - 116
  • [27] Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
    Mahoney, Emilia
    Byrd, John C.
    Johnson, Amy J.
    AUTOPHAGY, 2013, 9 (03) : 434 - 435
  • [28] Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
    Fabre, Claire
    Gobbi, Marco
    Ezzili, Cyrine
    Zoubir, Mustapha
    Sablin, Marie-Paule
    Small, Karen
    Im, Ellie
    Shinwari, Nabeegha
    Zhang, Da
    Zhou, Honghong
    Le Tourneau, Christophe
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1057 - 1064
  • [29] Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
    Claire Fabre
    Marco Gobbi
    Cyrine Ezzili
    Mustapha Zoubir
    Marie-Paule Sablin
    Karen Small
    Ellie Im
    Nabeegha Shinwari
    Da Zhang
    Honghong Zhou
    Christophe Le Tourneau
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1057 - 1064
  • [30] The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
    Konig, A
    Schwartz, GK
    Mohammad, RM
    AlKatib, A
    Gabrilove, JL
    BLOOD, 1997, 90 (11) : 4307 - 4312
12345